Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 674
- Registration Number
- NCT03412773
- Locations
- 🇺🇸
University of California - Hematology and Oncology, Los Angeles, California, United States
🇺🇸Cancer Treatment Centers of America - Oncology, Philadelphia, Pennsylvania, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1324
- Registration Number
- NCT03298451
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT03247088
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 54
- Registration Number
- NCT03178656
- Locations
- 🇨🇳
Hepatic surgery center, Tong ji Hospital, Wuhan, Hubei, China
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 5
- Registration Number
- NCT03170895
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients with Recurrent or Refractory Leukemia
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03132454
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 450
- Registration Number
- NCT03097848
- Locations
- 🇨🇳
Southwest Hospital, Chongqing, Chongqing, China
Paediatric Hepatic International Tumour Trial
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 450
- Registration Number
- NCT03017326
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Woluwe-Saint-Lambert, Belgium
🇮🇪Children's Health Ireland Crumlin, Dublin, Ireland
🇮🇱Schneider Children's Medical Center, Petach Tikva, Israel
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 64
- Registration Number
- NCT03009461
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.